Mohammed Mostafa Ibrahim1, Abd-Elgawad Helmy Abd-Elgawad2, Osama Abd-Elazeem Soliman2, Monica M Jablonski3. 1. Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN, USA ; Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. 2. Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. 3. Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
PURPOSE: We prepared and characterized topical ophthalmic formulations containing brimonidine-loaded bioadhesive cationic chitosan or anionic alginate nanoparticles (NPs) for sustained release of brimonidine as once daily regimen for management of glaucoma. METHODS: Nanoparticles were prepared using a spontaneous emulsification solvent diffusion method. Different concentrations of polymers, emulsifiers, and NPs stabilizers were used for formulation optimization. Nanoparticles were characterized regarding particle size, zeta potential, morphology, and drug content. Brimonidine-loaded NPs were incorporated into eye drops, a temperature-triggered in situ gelling system, and a preformed gel. They then were characterized regarding their pH, viscosity, uniformity of drug content, in vitro release characteristics, in vitro cytotoxicity, and in vivo intraocular pressure (IOP) lowering effects. RESULTS: Characteristics of optimized brimonidine-loaded chitosan and alginate NPs, respectively, are: particle size, 115.67 ± 3.58 and 157.67 ± 5.53 nm; zeta potential, +35.27 ± 3.39 and -37.8 ± 3.77 mV; encapsulation efficiency, 74.34% ± 2.05% and 70.40% ± 2.77%; drug loading, 11.81% ± 0.67% and 13.14% ± 0.90%; and yield, 87.91% ± 5.92% and 76.53% ± 3.32%. Transmission electron microscope (TEM) analyses revealed that NPs have spherical shapes with a dense core and distinct coat. Formulations possessed uniform drug content. Furthermore, pH and viscosity were compatible with the eye. Formulations showed a sustained release without any burst effect with a Higuchi non-Fickian diffusion mechanism. Cytotoxicity studies revealed that all formulations are biocompatible. Importantly, all formulations possessed a sustained IOP lowering effect compared to the marketed brimonidine tartrate eye drops. CONCLUSIONS: These formulations provide a great improvement in topical ocular brimonidine delivery. The application of a single drop is sufficient to provide extended IOP reduction, which should improve patient compliance. TRANSLATIONAL RELEVANCE: We have developed a novel biocompatible topical delivery system for brimonidine, a first line glaucoma medication. Once daily application should have positive effects on patient compliance and, therefore, preservation of vision.
PURPOSE: We prepared and characterized topical ophthalmic formulations containing brimonidine-loaded bioadhesive cationic chitosan or anionic alginate nanoparticles (NPs) for sustained release of brimonidine as once daily regimen for management of glaucoma. METHODS: Nanoparticles were prepared using a spontaneous emulsification solvent diffusion method. Different concentrations of polymers, emulsifiers, and NPs stabilizers were used for formulation optimization. Nanoparticles were characterized regarding particle size, zeta potential, morphology, and drug content. Brimonidine-loaded NPs were incorporated into eye drops, a temperature-triggered in situ gelling system, and a preformed gel. They then were characterized regarding their pH, viscosity, uniformity of drug content, in vitro release characteristics, in vitro cytotoxicity, and in vivo intraocular pressure (IOP) lowering effects. RESULTS: Characteristics of optimized brimonidine-loaded chitosan and alginate NPs, respectively, are: particle size, 115.67 ± 3.58 and 157.67 ± 5.53 nm; zeta potential, +35.27 ± 3.39 and -37.8 ± 3.77 mV; encapsulation efficiency, 74.34% ± 2.05% and 70.40% ± 2.77%; drug loading, 11.81% ± 0.67% and 13.14% ± 0.90%; and yield, 87.91% ± 5.92% and 76.53% ± 3.32%. Transmission electron microscope (TEM) analyses revealed that NPs have spherical shapes with a dense core and distinct coat. Formulations possessed uniform drug content. Furthermore, pH and viscosity were compatible with the eye. Formulations showed a sustained release without any burst effect with a Higuchi non-Fickian diffusion mechanism. Cytotoxicity studies revealed that all formulations are biocompatible. Importantly, all formulations possessed a sustained IOP lowering effect compared to the marketed brimonidine tartrate eye drops. CONCLUSIONS: These formulations provide a great improvement in topical ocular brimonidine delivery. The application of a single drop is sufficient to provide extended IOP reduction, which should improve patient compliance. TRANSLATIONAL RELEVANCE: We have developed a novel biocompatible topical delivery system for brimonidine, a first line glaucoma medication. Once daily application should have positive effects on patient compliance and, therefore, preservation of vision.
Authors: Maria de la Fuente; Manuela Raviña; Patrizia Paolicelli; Alejandro Sanchez; Begoña Seijo; Maria Jose Alonso Journal: Adv Drug Deliv Rev Date: 2009-12-01 Impact factor: 15.470
Authors: B Chiang; Y C Kim; A C Doty; H E Grossniklaus; S P Schwendeman; M R Prausnitz Journal: J Control Release Date: 2016-02-28 Impact factor: 9.776
Authors: Sumana R Chintalapudi; Doaa Maria; Xiang Di Wang; Jessica N Cooke Bailey; Pirro G Hysi; Janey L Wiggs; Robert W Williams; Monica M Jablonski Journal: Nat Commun Date: 2017-11-24 Impact factor: 14.919
Authors: Maria Mir; Saba Ishtiaq; Samreen Rabia; Maryam Khatoon; Ahmad Zeb; Gul Majid Khan; Asim Ur Rehman; Fakhar Ud Din Journal: Nanoscale Res Lett Date: 2017-08-17 Impact factor: 4.703
Authors: Miko Yamada; Hossam Tayeb; Hequn Wang; Nhung Dang; Yousuf H Mohammed; Sam Osseiran; Paul J Belt; Michael S Roberts; Conor L Evans; Frank Sainsbury; Tarl W Prow Journal: J Control Release Date: 2018-09-15 Impact factor: 9.776